New TAVR Devices: Better Results in Bicuspids

Courtesy of del Dr. Carlos Fava.

 

sapien_xt_sapien_3 TAVR devicesThe bicuspid aortic valve is highly anatomically challenging because of valve asymmetric calcification, increased annulus diameter, raphe calcification and ascending aorta dilation. The new valves have shown to improve results, but we still lack data on this group.

 

301 patients presenting bicuspid aortic valve undergoing transcatheter aortic valve replacement (TAVR) were analyzed. 199 of these patients receive a first generation valve (FG) (Sapien XT: 87 y CoreValve: 112) and 102 a new generation valve (NG) (Sapien 3: 91 y Lotus: 11).

 

Populations were similar, except for ejection fraction, which resulted lower in those receiving NG (52.9% vs. 47.5%; p=0.004).

 

Device success rate was higher in those receiving NG:

NG: 92.2%

FG: 80.9%

[p=0.01]

 

Mild or severe paravalvular leak was also lower with NG:

NG: 0%

FG: 8.5%

[p=0.002]

 

There were no differences in:

  • Stroke
  • Life threatening bleeding
  • Major vascular complications
  • Kidney function deterioration
  • Safety end points
  • Cardiovascular or all-cause mortality in both groups at 30 days and one year (4.3% and 14.1%).

 

At multivariable analyzis, EuroSCORE ≥20, major bleeding and kidney function deterioration was associated to mortality (stages 2 or 3).

 

Conclusion

TAVR evolution in patients with bicuspid valve disease is favorable. New generation devices are associated with less paravalvular leak and higher device success.

 

Editorial Comment

This is the largest series to compare new generation devices against prior devices in this complex scenario to show they are beneficial in terms of device success and absence of paravalvular leak, with no differences in the rest of end points at one year.

 

Surely, at longer follow up, the presence of mild or severe paravalvular leak would translate into death.

 

Original Title: Transcatheter Aortic Valve Replacement with Early-and New-Generation Devices in Bicuspid Aortic valve Stenosis.

Reference: Sung-Han Yoon et al. J Am Coll Cardiol 2016;68:1195-205.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

We value your opinion. You are more than welcome to leave your comments, questions or suggestions here below.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....